Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330161
Status:
COMPLETED
Last Update Posted:
2014-05-26
First Post:
2006-05-25
Brief Title:
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Evaluation of Suberoylanilide Hydroxamic Acid NSC 701852 in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well vorinostat works in treating patients with progressive metastatic prostate cancer Drugs used in chemotherapy such as vorinostat work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Detailed Description:
PRIMARY OBJECTIVES
I To evaluate the efficacy of oral SAHA in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy as measured by the proportion of patients not progressed at 6 months
SECONDARY OBJECTIVES
I To evaluate the safety of oral SAHA in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy
II To assess the objective response rate of oral SAHA in patients with measurable disease when present
III To assess the rate of PSA decline of 50 IV To assess progression free and median survival in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy
V To evaluate pre and post-treatment tumor biopsies when available for the presence of changes in the expression of AR and Hsp90 client proteins Thioredoxin Thioredoxin Binding Protein HDAC 3 class I HDAC 7 class II EZH2 and p21 expression
VI To determine the effects of oral SAHA on IL-6 soluble IL-6 receptor and soluble gp130 levels in the blood
VII To determine the accumulation and biodistribution of 18FDHT and correlate these findings with standard FDG PET radionuclide bone scan CT andor MRI scans as well as 18FDHT pharmacokinetics and tumor tissue staining for androgen receptor AR and Hsp90 client proteins this applies only to patients at MSKCC under a separate protocol 00-095
OUTLINE This is a multicenter study
Patients receive oral vorinostat SAHA once daily on days 1-21 Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity Patients who achieve complete response CR after 4 courses receive an additional 3 courses All other patients may continue treatment in the absence of disease progression or unacceptable toxicity
Blood samples are taken on day 15 of course 1 day 1 of course 2 during the last week of course 4 and at completion of study treatment Blood is examined for interleukin IL-6 IL-6 receptor and gp130 levels
After completion of study treatment patients are followed periodically for survival
I To evaluate the efficacy of oral SAHA in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy as measured by the proportion of patients not progressed at 6 months
SECONDARY OBJECTIVES
I To evaluate the safety of oral SAHA in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy
II To assess the objective response rate of oral SAHA in patients with measurable disease when present
III To assess the rate of PSA decline of 50 IV To assess progression free and median survival in patients with castrate metastatic prostate cancer who have progressed on one prior chemotherapy
V To evaluate pre and post-treatment tumor biopsies when available for the presence of changes in the expression of AR and Hsp90 client proteins Thioredoxin Thioredoxin Binding Protein HDAC 3 class I HDAC 7 class II EZH2 and p21 expression
VI To determine the effects of oral SAHA on IL-6 soluble IL-6 receptor and soluble gp130 levels in the blood
VII To determine the accumulation and biodistribution of 18FDHT and correlate these findings with standard FDG PET radionuclide bone scan CT andor MRI scans as well as 18FDHT pharmacokinetics and tumor tissue staining for androgen receptor AR and Hsp90 client proteins this applies only to patients at MSKCC under a separate protocol 00-095
OUTLINE This is a multicenter study
Patients receive oral vorinostat SAHA once daily on days 1-21 Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity Patients who achieve complete response CR after 4 courses receive an additional 3 courses All other patients may continue treatment in the absence of disease progression or unacceptable toxicity
Blood samples are taken on day 15 of course 1 day 1 of course 2 during the last week of course 4 and at completion of study treatment Blood is examined for interleukin IL-6 IL-6 receptor and gp130 levels
After completion of study treatment patients are followed periodically for survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA046592 | NIH | CTEP | httpsreporternihgovquickSearchP30CA046592 |
| NCI-2012-03067 | REGISTRY | None | None |
| UMCC 2005127 | OTHER | None | None |
| 6862 | OTHER | None | None |
| N01CM62206 | NIH | None | None |
| N01CM62201 | NIH | None | None |
| U01CA062491 | NIH | None | None |